French researchers have reported a 35.7% disease-free survival in 120 patients with non-metastatic inflammatory breast cancer treated with a high-dose chemotherapy regimen of fluorouracil (5-FU), Ellence® (epirubicin) and Cytoxan® (cyclophosphamide) (FEC-HD) with or without Granocyte® (lenograstim). The details of this long-term follow-up were published as an advance of print publication in Cancer on October 19, 2006. ....
To read the complete article, please fallow this link to CancerConsultants.com.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment